Content
All Posts > Content under Healthcare
Futures Rise On Government Funding Deal; Most Global Markets Closed For Holiday
Article By:
Tyler Durden
Read
Monday, May 1, 2017 6:57 AM EDT
With much of Europe and Asia, including the U.K., France, Germany and China markets closed for Labor Day, Asian stocks and the dollar rose buoyed by news that Congress had reached a deal to keep the US government funded through the end of September.
Green Bell Bottoms, Rising Interest Rates And Buyable Stocks
Article By:
Marc Gerstein
Read
Sunday, April 30, 2017 9:33 PM EDT
It’s time to start thinking about debt-related fundamentals in ways that have been largely irrelevant since I looked good in those green bell bottoms.
In this article: BAX, BBY, CI, CNC, DLPH, FL, HBI, HRB, JNPR, PVH, SIG, TJX, TSN, UHS, VLO, WDC, AMAT, DLTR, ROST, FOXA
Novartis Receives FDA Approval For An Acute Myeloid Leukemia Drug
Article By:
Terry Chrisomalis
Read
Sunday, April 30, 2017 11:36 AM EDT
On Friday, Novartis stated that it had won FDA approval for Rydapt, which is a drug developed to treat patients with Acute Myeloid Leukemia -- AML.
In this article: NVS
Economic Events Of The Coming Week - Sunday, April 30
The Tech Sector's Strong Earnings Power
Article By:
Sheraz Mian
Read
Sunday, April 30, 2017 9:46 AM EDT
Apple will report results after the market’s close on Tuesday, May 2nd.The company is expected to report $2.01 per share on $52.6 billion in revenues, up +5.9% and +4.1% from the year-earlier levels, respectively.
Aeterna Zentaris Climbs On Phase 3 Announcement
Article By:
Terry Chrisomalis
Read
Sunday, April 30, 2017 3:48 AM EDT
If Aeterna Zentaris posts positive results on Monday, the stock will soar much higher. Of course as with anything in biotech, there is some risk involved. The results could possibly end up being mixed or even worse, fail altogether.
Week In Review: Cathay Fortune Pays $186 Million For German Diagnostic Company
Article By:
ChinaBio® Today
Read
Saturday, April 29, 2017 1:45 PM EDT
Cathay Fortune International, a Shanghai healthcare private equity firm, will acquire Berlin's Epigenomics AG for $186 million in cash. Cathay will acquire Epigenomics through a subsidiary, Blitz F16-83.
The Good, The Bad And The Ugly: Gilead Sciences
Video By:
Dr. Joseph Belmonte
Watch
Friday, April 28, 2017 4:08 PM EDT
Gilead is not your father's growth stock anymore nor should it be yours either.
In this video: GILD
IDEXX Laboratories Boosts Outlook Amid Strong Q1 Results
Article By:
Lorimer Wilson
Read
Friday, April 28, 2017 10:39 AM EDT
IDEXX Laboratories, Inc. early Friday posted much better than expected first quarter earnings results and lifted its full-year forecast, sending its shares significantly higher in morning trading.
In this article: IDXX
Bristol-Myers Squibb: Strong Earnings Could Warrant Higher Dividend Growth Ahead
Article By:
SureDividend
Read
Friday, April 28, 2017 10:01 AM EDT
Bristol-Myers has a low payout ratio, a high level of profitability, and a strong balance sheet. These are the ingredients that should allow the company to raise its future dividend increases, possibly in the mid-single digit range.
In this article: BMY
A Deluge And An Eclipse
Article By:
Marvin R Clark
Read
Thursday, April 27, 2017 11:33 PM EDT
Today brought a deluge of earnings.Google parent Alphabet posted a 29 percent rise in quarterly profit, driven by a surge in advertising on mobiles and its popular YouTube video service.
In this article: BMY, DPZ, F, KKR, LNKD, LUV, UPS, AMZN, GOOG, INTC, MSFT, SBUX, AAL, ABBV, GOOGL, CCV
The Short-Term Trend
Article By:
Douglas Gammons
Read
Thursday, April 27, 2017 5:25 PM EDT
The market has stalled a bit after the big breakout. This is starting to look like a rally up to the top of the range. Then again, we are in the middle of earnings and there is tons of news everyday.
AbbVie’s Humira Revenue Up 15% (Despite Patent Cliff Fears)
Article By:
SureDividend
Read
Thursday, April 27, 2017 3:54 PM EDT
Will discuss why AbbVie’s earnings report was better than anticipated, and what investors can expect from this stock moving forward.